New antibody EB070 begins first human safety trial
NCT ID NCT07413536
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests the safety of a new drug called EB070, an antibody that blocks a protein involved in allergic inflammation. Thirty-six healthy adults will receive a single injection of either EB070 or a placebo at increasing doses. The study monitors side effects and how the body processes the drug over about 3.5 months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- EB070 (anti-TSLP monoclonal antibody)
- What this could lead to
- If safe, this could pave the way for testing EB070 as a treatment for allergic or inflammatory conditions like asthma.
- What could go wrong
- This is an early Phase 1 safety study in healthy people, not patients. It cannot show if the drug works for any disease, and side effects are unknown.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTH ADULT SUBJECTS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can the right work-rest rhythm and a massage gun soften stiff calf muscles?
- Beetroot boost: does more nitrate mean more endurance?
- What makes people move? new study probes the secrets of physical activity
- New daily pill TIX100 takes first step toward tackling obesity
- New skin ointment takes first step toward treating inflammatory conditions
- One yoga session may boost heart health overnight